14 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 35551917 | Resolvin E1 attenuates doxorubicin-induced endothelial senescence by modulating NLRP3 inflammasome activation. | 2022 Jul | 2 |
2 | 33952842 | [Doxorubicin directly induced fibrotic change of cardiac fibroblasts]. | 2021 | 2 |
3 | 34120620 | Biomimetic nanotherapy: core-shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma. | 2021 Jun 13 | 1 |
4 | 34145895 | Non-invasive transcutaneous vagal nerve stimulation improves myocardial performance in doxorubicin-induced cardiotoxicity. | 2021 Jun 18 | 1 |
5 | 34547383 | Doxorubicin suppresses chondrocyte differentiation by stimulating ROS production. | 2021 Dec 1 | 1 |
6 | 25275022 | Differential expression of VEGF and IL-1alpha after photodynamic treatment in combination with doxorubicin or taxotere. | 2014 Oct | 2 |
7 | 20599921 | Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. | 2010 Sep 25 | 3 |
8 | 12415617 | Interleukin-1 alpha increases the cytotoxic activity of etoposide against human osteosarcoma cells. | 2002 Jan-Feb | 1 |
9 | 7803193 | A recombinant human interleukin-1 beta protects adriamycin-induced toxicity. Adriamycin cardiotoxicity and interleukin-1. | 1993-1994 | 3 |
10 | 8317554 | Age-dependent basal level and induction capacity of copper-zinc and manganese superoxide dismutase and other scavenging enzyme activities in leukocytes from young and elderly adults. | 1993 Jul | 1 |
11 | 8453624 | Protective effects of recombinant human interleukin-1 alpha in doxorubicin-treated normal and tumor-bearing mice. | 1993 Apr 1 | 2 |
12 | 8512591 | Synergistic antiproliferative effects of interleukin-1 alpha and doxorubicin against the human ovarian carcinoma cell line (NIH:OVCAR-3). | 1993 May 25 | 4 |
13 | 1292755 | Synergistic antiproliferative effects of the combination of interleukin-1 alpha and doxorubicin against human melanoma cells. | 1992 | 7 |
14 | 2565969 | Doxorubicin is a potent inhibitor of interleukin 1 induced cartilage proteoglycan resorption in-vitro. | 1989 Jan | 4 |